| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
| 03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
| 31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
| 05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
| Carolyn Cross |
156,314,029 |
£13,677,478 |
| Nicolas Loebel |
3,538,991 |
£309,662 |
| Junaid Bajwa |
1,193,697 |
£104,448 |
| Jean Duvall |
1,163,529 |
£101,809 |
| Jean Charest |
353,356 |
£30,919 |
| Carolyn Cross |
119,258,222 |
£10,435,094 |
| M&G Plc |
67,254,901 |
£5,884,804 |
| hInsight-NX, LLC |
42,272,654 |
£3,698,857 |
| Robert Cross |
37,772,652 |
£3,305,107 |
| Albemarle Life Sciences Fund |
15,105,882 |
£1,321,765 |
| CRUX Asset Management |
9,298,090 |
£813,583 |
| Chelverton Asset Management |
7,957,311 |
£696,265 |
| 15:30 |
3 @ 8.50p |
| 15:04 |
65,000 @ 8.81p |
| 15:04 |
46,670 @ 8.75p |
| 14:52 |
56,000 @ 8.80p |
| 11:15 |
16,901 @ 8.68p |
| Chair |
Jean Charest |
| CEO |
Carolyn Cross |
Top of Page
You are here:
research